AI Science Tracker

IBM Research

4 discoveries from 2021 to 2026

Discoveries

Foundation model and generative AI yield 3CL protease inhibitors confirmed at sub-micromolar IC50

An AI-assisted 3CL-protease inhibitor study selected 249 molecules from about five million generated candidates and evaluated 18 using free-energy perturbation. Five molecules were experimentally tested; all five inhibited the target below 1 micromolar IC50, and one inhibited more strongly than its lead. MMELON activity predictions had Pearson R=0.72 in a blind test. This summary is limited to the abstract and November 13, 2026 publication metadata; it does not establish antiviral efficacy in people.

Technology: MMELON biomedical foundation model with generative molecular models

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Five synthesized molecules tested for 3CL-protease inhibition after computational candidate generation and filtering.
  • Still unknown: Source checking does not establish independent confirmation. Review date: 2026-11-15.
  • AI role: Generative models produced candidate molecules; the MMELON foundation model predicted activity and supported downselection.

Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID%3A43024107&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

IBM Research

A chemical foundation model guides high-conductivity electrolyte formulation

Researchers fine-tuned the SMI-TED chemical foundation model on 13,666 literature measurements of ionic conductivity and screened 100,000 generated electrolyte formulations. Sixteen selected formulations were measured experimentally, with seven exceeding 10 mS/cm. A model-generated LiFSI formulation measured 19.14 mS/cm at room temperature, 82% above the best literature value in the paper’s comparison; the model had predicted 10.52 mS/cm. Conductivity is only one electrolyte property and does not establish electrochemical stability, safety or battery performance. The article was published 2025-08-30; a later correction changed an author name only.

Technology: SMI-TED chemical foundation model fine-tuned for electrolyte mixture ionic-conductivity prediction and generative screening

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Sixteen selected formulations were measured by triplicate EIS at 20 °C; seven exceeded 10 mS/cm. A generated LiFSI electrolyte measured 19.14 mS/cm, compared with a model prediction of 10.52 mS/cm and 82% higher conductivity than the best literature value used in the paper comparison.
  • Still unknown: High ionic conductivity alone does not establish electrochemical stability, compatibility with particular electrodes, safety, cycle life or commercial battery performance.
  • AI role: SMI-TED was fine-tuned on literature ionic-conductivity data and screened 100,000 generated formulations; selected candidates were prepared and measured experimentally.

Evidence sources: https://www.nature.com/articles/s41524-025-01774-4 · https://www.nature.com/articles/s41524-025-01804-1

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Primary publisher full text including methods, measured outcomes, affiliations and publication date; primary publisher correction..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Sequence-conditioned CogMol designs SARS-CoV-2 spike and main-protease inhibitors

IBM Research and academic collaborators used the CogMol deep generative foundation model to design compounds from target protein sequence information alone for SARS-CoV-2 spike receptor-binding domain and main protease. In vitro inhibition was reported for two of four synthesized candidates for each target; the most potent spike-RBD inhibitor also showed activity against multiple variants in live-virus neutralization assays.

Technology: CogMol, a sequence-conditioned deep generative foundation model using a molecular variational autoencoder and protein–ligand binding predictor

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: In vitro inhibition was reported for two of four synthesized candidates for each target; the most potent spike-RBD inhibitor also showed activity against multiple variants in live-virus neutralization assays.
  • Still unknown: The source describes a proof of concept with a small selected synthesis set from roughly 100 ranked designs. Only in-vitro target assays were performed; the leading RBD inhibitor was also tested in live-virus neutralization against variants. The paper says ADME attributes were not experimentally validated and further work is needed to confirm inhibitor binding mechanisms. These are preclinical leads, not medicines or demonstrated clinical benefit.
  • AI role: The team sampled CogMol conditioned on each target's amino-acid sequence to generate candidate small molecules; candidates were filtered and ranked in silico, synthesized and assayed. The model generated compounds without target-specific fine-tuning or target-structure input at inference; assays found micromolar inhibition for 2/4 synthesized candidates for each target.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10284550/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 66 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

IBM Research

IBM designs two new antimicrobial peptides with generative models

Over 48 days, 20 candidates were designed, synthesized, and tested; two showed activity against several pathogens, including multidrug-resistant Klebsiella pneumoniae. In vitro and mouse tests only, with no demonstration of safety or efficacy in humans.

Technology: Generative autoencoder and CLaSS

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: 20 generative-model candidates were synthesised and tested; two were active against several pathogens, with in vitro and mouse tests.
  • Still unknown: No demonstration of safety or efficacy in humans, and no human trials are mentioned.
  • AI role: Generative models designed candidate antimicrobial peptides.

Evidence sources: https://research.ibm.com/blog/ai-finds-new-peptides · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A10.1038/s41551-021-00689-x&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: blog. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 508 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.